ALK tyrosine kinase inhibitors achieve 58.5% objective response rate in ALK-positive non-small cell lung cancer
New data shows how ALK inhibitors treat lung cancer
This meta-analysis of 6382 adults with ALK-positive non-small cell lung cancer (NSCLC) found an overall objective response rate (ORR) of 58.…
Recent analysis shows that newer generations of targeted drugs offer significant response rates for patients with specific types of lung can…
Systematic review of lung cancer in pregnancy reports treatment patterns and outcomes
Women with lung cancer during pregnancy need careful treatment plans and close medical care for best results
This systematic review synthesized 96 cases of lung cancer diagnosed during pregnancy. It found that 58.9% had actionable driver alterations…
A review of ninety-six cases shows most mothers had advanced cancer when diagnosed. Many received chemotherapy or targeted drugs safely, wit…